Premium
Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong
Author(s) -
Chan Henry LikYuen,
Tsang Owen TakYin,
Hui YeeTak,
Fung James,
Lui Grace ChungYan,
Lai ChingLung,
Wong Grace LaiHung,
Chan KamHon,
But David YiuKuen,
Lai MoonSing,
Lao WaiCheung,
Chan Carmen KaMan,
Lam YipShun,
Seto WaiKay,
Li Carlton,
Yuen ManFung,
Wong Vincent WaiSun
Publication year - 2017
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13663
Subject(s) - ombitasvir , paritaprevir , dasabuvir , medicine , ribavirin , ritonavir , daclatasvir , hepatitis c , sofosbuvir , gastroenterology , hepatitis c virus , virology , viral load , virus , antiretroviral therapy
Background and Aim In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong. Methods We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program. Results Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co‐infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty‐five (85%) patients received 12‐week treatment and six patients received 24‐week treatment; 26 (63%) patients received ribavirin combination. Thirty‐nine (95%; 95% confidence interval 88.5–100%) patients had undetectable HCV RNA at 12‐week post‐treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation. Conclusions Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real‐life clinical setting in Hong Kong.